

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

***APPLICATION NUMBER:***  
**21-372/S008/S010**

**STATISTICAL REVIEW(S)**



U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Translational Science  
Office of Biostatistics

## STATISTICAL REVIEW AND EVALUATION CLINICAL STUDIES

NDA/Ser Nr: 21372/S008, (b) (4)  
DATE RECEIVED: April 27, 2007  
PDUFA DATE: March 4, 2008  
DRUG NAME: Aloxi (palonosetron HCL) Intravenous Injection  
INDICATION: Prevention of postoperative nausea and vomiting  
following elective abdominal or gynecological  
laparoscopic surgery  
APPLICANT: Helsinn Healthcare SA  
REVIEW PRIORITY: Standard  
BIOMETRICS DIVISION: Division of Biometrics 3 (HFD-725)  
STATISTICAL REVIEWER: Wen-Jen Chen, PhD  
CONCURRING REVIEWER: Mike Welch, PhD, Dep. Dir., DB3  
MEDICAL DIVISION: Gastroenterology Products (HFD-180)  
CLINICAL TEAM: Nancy Snow, MD, Hugo Gallo-Torres, MD (TL)  
PROJECT MANAGER: Jagjit Grewal, MPH  
STATISTICAL KEYWORDS: Clinical studies; NDA review; Multiplicity  
adjustments; Baseline adaptive randomization.

## TABLE OF CONTENTS

|            |                                                  |           |
|------------|--------------------------------------------------|-----------|
| <b>1.0</b> | <b>EXECUTIVE SUMMARY OF STATISTICAL FINDINGS</b> | <b>3</b>  |
| 1.1        | Conclusions and Recommendations                  | 3         |
| 1.2        | Brief Overview of Clinical Studies               | 3         |
| 1.3        | Statistical Issues and Findings                  | 4         |
| 1.3.1      | Study PALO-04-06                                 | 4         |
| 1.3.2      | Study PALO-04-07                                 | 6         |
| <b>2.0</b> | <b>INTRODUCTION</b>                              | <b>6</b>  |
| 2.1        | Overview                                         | 6         |
| 2.1.1      | Outline for Study PALO-04-06                     | 7         |
| 2.1.2      | Overview for Study PALO-04-07                    | 8         |
| 2.2        | Data Sources                                     | 9         |
| <b>3.0</b> | <b>STATISTICAL EVALUATION</b>                    | <b>10</b> |
| 3.1        | Evaluation of Efficacy for Study PALO-04-06      | 10        |
| 3.1.1      | Study Design and Endpoints                       | 10        |
| 3.1.2      | Statistical Methodologies                        | 13        |
| 3.1.3      | Applicant's Efficacy Analysis and Conclusion     | 19        |
| 3.1.3.1    | Co-primary Endpoint Analysis                     | 19        |
| 3.1.3.2    | Secondary Endpoint Analysis                      | 22        |
| 3.1.4      | Statistical Reviewer's Analysis and Comments     | 28        |
| 3.2        | Evaluation of Safety for Study PALO-04-06        | 35        |
| <b>4.0</b> | <b>FINDINGS IN SPECIAL/SUBGROUP POPULATIONS</b>  | <b>35</b> |
| 4.1        | Gender, Race, and Age for Study PALO-04-06       | 35        |
| 4.2        | Other Special/Subgroup Populations               | 37        |
| <b>5.0</b> | <b>SUMMARY AND CONCLUSIONS</b>                   | <b>37</b> |
| 5.1        | Statistical Issues and Collective Evidence       | 37        |
| 5.1.1      | Study PALO-04-06                                 | 37        |
| 5.1.2      | Study PALO-04-07                                 | 38        |
| 5.2        | Conclusions and Recommendations                  | 38        |

## 1.0 EXECUTIVE SUMMARY OF STATISTICAL FINDINGS

### 1.1 Conclusions and Recommendations

Based on review of the pivotal Study Palo-04-06 and the supportive Study Palo-04-07, palonosetron 0.075 mg is supported by substantial evidence of efficacy for use in prevention of postoperative nausea and vomiting for the first 24 hour postoperative observation period following elective abdominal or gynecological laparoscopic surgery.

### 1.2 Brief Overview of Clinical Studies

Two phase 3 Studies PALO-04-06 and PALO-04-07 were submitted by the applicant to support Aloxi for the prevention of postoperative nausea and vomiting (PONV) (b) (4)

Supplement 008 refers to the PONV indication (b) (4)

(b) (4)

(b) (4)

For the PONV indication, due to partial unblinding of treatment codes, Study PALO-04-07 is considered a supportive study, and Study PALO-04-06 is considered a single principal study and thus required to show substantial evidence of efficacy, with the uncompromized data from the PALO-04-07 trial providing supportive evidence. However, based on that data, the applicant's efficacy analysis for study PALO-04-07 failed to show effectiveness of palonosetron over placebo for either the 0-24 or 24-72 hour periods for any of the dose groups (0.025 mg, 0.05 mg, and 0.075 mg). Thus the data from Study PALO-04-07 do not provide positive support for the pivotal Study PALO-04-06. (For more detail review of Study 07, refer to Section 2.1.2.)

Study PALO-04-06 was designed as a randomized, double-blind, multi-center, parallel group, placebo-controlled phase 3 trial to evaluate the efficacy and safety of single i.v. doses of palonosetron (0.025 mg, 0.050 mg, or 0.075 mg) versus placebo for the prevention of PONV from 0 to 24 hours and 24 to 72 hours in the post-operative period in male and female outpatients undergoing elective laparoscopic abdominal or gynecological surgery with general anesthesia. In this study, outpatients were defined as those expected to go home on the same day as surgery (no overnight stay). All laparoscopic procedures took place under general anesthesia.

The population for this study consisted of eligible male or female outpatients with age  $\geq 18$ , undergoing elective laparoscopic abdominal or gynecological surgery, who met the inclusion and not the exclusion criteria for the study and gave their informed consent to participate in the study.

The duration of this study was 12 and one-half months: first patient enrolled on 23 May 2005 and last patient completed on 12 June 2006. A total of 43 investigators from two countries (USA and Romania) participated in the study: 36 from USA and 7 from Romania.

The study drug was administered as a single i.v. dose of palonosetron or placebo for the prevention of PONV immediately (no more than 5 minutes) prior to induction of anesthesia (Study Day 1). In addition, efficacy and safety were assessed on the day of study drug administration at Visit 2 (Study Day 1) and at a final visit (Study Days 6 to 10) following the surgical procedure. The primary endpoint for this study was Complete Response (CR) defined as the absence of nausea and vomiting during the specified period.

The study had two co-primary objectives as follows:

1. To compare the effect of a single IV dose of palonosetron (0.025 mg, 0.050 mg or 0.075 mg) versus a single IV dose of placebo on CR during the first 24-hour postoperative observation period.
2. To compare the effect of a single IV dose of palonosetron (0.025 mg, 0.050 mg or 0.075 mg) versus a single IV dose of placebo on CR during the first 24-72 hour postoperative observation period.

A total of 639 patients were screened for this study, of which 574 patients were randomized into one of the four treatment arms: single i.v. doses of palonosetron (0.025 mg, 0.050 mg, or 0.075 mg) or placebo. A total of 547 patients were treated. The applicant used an adaptive randomization method to stratify and assign subjects to the four treatment groups in a 1:1:1:1 ratio.

### 1.3 Statistical Issues and Findings

#### 1.3.1 Study PALO-04-06

For the first 24 hour observation period, superiority of palonosetron over placebo was demonstrated for the 0.05 and 0.075 mg dose groups showing efficacy evidence in prevention of postoperative nausea and vomiting following elective abdominal or gynecological laparoscopic surgery. However, the efficacy comparisons performed by the applicant for the 0.025 mg dose for the 0-24 hour period did not show superiority; and for the 24-72 hour postoperative observation period, all three palonosetron doses (0.025 mg, 0.05 mg, and 0.075 mg) failed to demonstrate superiority to placebo.



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.